1. Are Heart-Lung Transplant Recipients Protected From Developing Bronchiolitis Obliterans Syndrome? 
Susan D. Moffatt-Bruce, MD, PhD, John Karamichalis, MD, Robert C. Robbins, MD, Richard I. Whyte, MD, James Theodore, MD, Bruce A. Reitz, MD 
The Annals of Thoracic Surgery 
Volume 81, Issue 1, Pages (January 2006)
DOI: /j.athoracsur
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
The incidence of cytomegalovirus (CMV) infection in heart-lung transplant (HLT; ♦) recipients was 58%, 59%, and 62% at 1, 3, and 5 years, respectively. The incidence of cytomegalovirus infection in the double-lung transplant (DLT; ■) recipients was significantly less at 45%, 47%, and 47% at 1, 3, and 5 years, respectively (p < 0.05).
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
The incidence of bronchiolitic obliterans syndrome (BOS) in the heart-lung transplant (HLT; ♦) recipients was 15%, 41%, and 48% at 1, 3, and 5 years, respectively. The incidence of bronchiolitic obliterans syndrome in the double-lung transplant (DLT; ■) recipients was 14%, 33%, and 46% at 1, 3, and 5 years, respectively. There was no statistically significant difference between these groups with respect to bronchiolitic obliterans syndrome.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions